SynthesisInflammopharmacology2025
Efficacy of curcumin/turmeric on inflammation and oxidative stress in prediabetes and type 2 diabetes: a systematic review and dose-response meta-analysis.
Synthesis in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.International journal of molecular sciences · 2026Trial
- Green spectrophotometric methods for the determination of metformin-curcumin combination: ICH validation and preliminary bioanalytical applications.Scientific reports · 2026Article
- The Use of Curcumin to Target Oxidative Stress and Inflammation in Type 2 Diabetes Mellitus and Its Complications: Molecular Mechanisms and Therapeutic Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Review
- Curcumin's Protective Effects Against HMolecules (Basel, Switzerland) · 2026Review
- Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026Review
- A Review of Curcumin in Chronic Disease Management: Anti-Inflammatory Pathways, Antioxidant Activity, and Therapeutic Advances.Journal of nutrition and metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation and oxidative stress are central to the development and progression of prediabetes and diabetes. Curcumin, the main bioactive component of turmeric, exhibits anti-inflammatory and antioxidant properties, though evidence from human randomized controlled trials (RCTs) remains inconsistent. This systematic review and meta-analysis evaluated the effects of curcumin/turmeric supplementation on inflammatory and oxidative stress biomarkers in individuals with prediabetes and diabetes. Comprehensive searches of PubMed, ISI Web of Science, and Scopus up to August 2025 identified RCTs comparing curcumin/turmeric supplementation with controls, reporting biomarkers such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), malondialdehyde (MDA), glutathione (GSH), and total antioxidant capacity (TAC). Data from 31 effect sizes across 28 RCTs were pooled using a random-effects model, with subgroup and meta-regression analyses to explore heterogeneity. Curcumin/turmeric supplementation significantly reduced CRP (SMD: - 0.50), TNF-α (SMD: - 1.70), IL-6 (SMD: - 2.97), and MDA (SMD: - 1.31), while significantly increasing GSH (SMD: 1.72) and TAC (SMD: 1.03). Greater improvements in CRP, GSH, and TAC were observed with unformulated curcumin and higher doses (≥ 1 g/day). Publication bias was detected for CRP and GSH, and the overall certainty of evidence was rated low for all biomarkers due to substantial heterogeneity. In conclusion, curcumin/turmeric supplementation may beneficially modulate inflammatory and oxidative stress biomarkers in prediabetes and diabetes, though further high-quality, large-scale RCTs are needed to confirm these findings and determine optimal formulations and dosages.
Indexed as
Identifiers
41240262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.